Literature DB >> 1779992

Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei.

V Satchidanandam1, F Zavala, B Moss.   

Abstract

A recombinant vaccinia virus was constructed which expressed the circumsporozoite protein of Plasmodium berghei. Four different strains of mice belonging to different haplotypes were immunized with the recombinant virus. The antibody response to the circumsporozoite protein as well as to vaccinia virus varied among the strains, independently of each other. The anti-circumsporozoite protein titers were comparable to that obtained on immunization with irradiated sporozoites. Spleen cells from H2d mice immunized with P. berghei sporozoites showed a significant proliferative response when cultured in vitro with a low multiplicity of the recombinant vaccinia virus. A weak cytotoxic T lymphocyte response specifically targeting the circumsporozoite protein could be identified in spleens of BALB/c (H2d) mice immunized with vaccinia virus when BALB 3T3 cells transformed with a plasmid expressing the circumsporozoite protein under control of the simian virus 40 promoter were used as target cells in the cytotoxic T lymphocyte assay. However, none of the recombinant virus-immunized animals could be protected from a challenge of sporozoites even at the lowest dose of parasite used.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1779992     DOI: 10.1016/0166-6851(91)90167-5

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  7 in total

Review 1.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

2.  Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Authors:  D E Lanar; J A Tine; C de Taisne; M C Seguin; W I Cox; J P Winslow; L A Ware; E B Kauffman; D Gordon; W R Ballou; E Paoletti; J C Sadoff
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

Review 3.  Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections.

Authors:  D L Doolan; S L Hoffman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-09-29       Impact factor: 6.237

4.  NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors:  J A Tine; D E Lanar; D M Smith; B T Wellde; P Schultheiss; L A Ware; E B Kauffman; R A Wirtz; C De Taisne; G S Hui; S P Chang; P Church; M R Hollingdale; D C Kaslow; S Hoffman; K P Guito; W R Ballou; J C Sadoff; E Paoletti
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

5.  Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity.

Authors:  D L Doolan; M Sedegah; R C Hedstrom; P Hobart; Y Charoenvit; S L Hoffman
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

6.  Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virus.

Authors:  M Theisen; G Cox; B Høgh; S Jepsen; J Vuust
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

Review 7.  Viral vectors for malaria vaccine development.

Authors:  Shengqiang Li; Emily Locke; Joseph Bruder; David Clarke; Denise L Doolan; Menzo J E Havenga; Adrian V S Hill; Peter Liljestrom; Thomas P Monath; Hussein Y Naim; Christian Ockenhouse; De-chu C Tang; Kent R Van Kampen; Jean-Francois Viret; Fidel Zavala; Filip Dubovsky
Journal:  Vaccine       Date:  2006-08-01       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.